“Long-Term Improvements Observed in Tralokinumab-Treated Patients With Moderate-to-Severe Atopic Dermatitis: An ECZTEND Interim Analysis”. 2021. SKIN The Journal of Cutaneous Medicine 5 (6): s59. https://doi.org/10.25251/skin.5.supp.59.